Passive antibody dependent cell-mediated activation

Patent metadata

Field	Value
Publication number	US-11459378-B2
Application number	US-201816480293-A
Country	US
Kind code	B2
Filing date	Jan 30, 2018
Priority date	Jan 30, 2017
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

In certain embodiments, described herein is a method of treating a subject infected with a pathogen encoding an Fc-binding protein comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody. Also described herein is a method for treating cancer in a subject undergoing oncolytic viral therapy comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody. Further described herein is a method of activating natural killer (NK) cells in a subject infected with a pathogen, comprising administering to the subject a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody.

First claim

What is claimed is:

1. A method of treating a subject infected with a pathogen expressing an Fc-binding protein comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition consisting of an Fc fragment of a human immunoglobulin G 1 (IgG1) antibody that binds to an FcγR on an immune effector cell at a first region and the pathogen-encoded Fc binding protein at a second region, wherein the first region is different than the second region, and wherein the pathogen-encoded Fc binding protein is glycoprotein E (gE) or 68 kDa-glycoprotein (gp68).

2. A method for treating a cancer in a subject undergoing oncolytic viral therapy comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition consisting of an Fc fragment of a human immunoglobulin G 1 (IgG1) antibody that binds to the pathogen-encoded Fc binding protein but does not bind to an FcγR on an immune effector cell, and wherein the pathogen-encoded Fc binding protein is glycoprotein E (gE) or 68 kDa-glycoprotein (gp68).

3. The method of claim 1 , wherein the Fc fragment of the IgG1 antibody comprises SEQ ID NO: 1.

4. The method of claim 1 , wherein the FcγR is CD16a.

5. The method of claim 1 , wherein the pathogen is herpes simplex virus 1 (HSV-1).

6. The method of claim 1 , wherein the pathogen is a cytomegalovirus.

7. The method of claim 2 , wherein the Fc fragment of the IgG1 antibody comprises SEQ ID NO: 2.

8. The method of claim 2 , wherein the oncolytic viral therapy comprises administering to the subject a recombinant oncolytic herpes simplex virus (oHSV).

9. A method of activating natural killer (NK) cells in a subject infected with a pathogen, comprising administering to the subject a pharmaceutical composition consisting of an Fc fragment of a human immunoglobulin G 1 (IgG1) antibody that binds to an FcγR on an immune effector cell at a first region and the pathogen-encoded Fc binding protein at a second region, wherein the first region is different than the second region, and wherein the pathogen-encoded Fc binding protein is glycoprotein E (gE) or 68 kDa-glycoprotein (gp68).

10. The method of claim 7 , wherein the pathogen is herpes simplex virus 1 (HSV-1).

11. The method of claim 7 , wherein the pathogen is a cytomegalovirus.

12. The method of claim 7 , wherein the FcγR is CD16a.

13. The method of claim 7 , wherein the Fc fragment of the IgG1 antibody comprises SEQ ID NO: 1.

Assignees

• Ohio State Innovation Foundation

Inventors

• Caligiuri Michael
• Yu Jianhua
• Dai Hongsheng

Classifications

• C07K2317/72

  Increased effector function due to an Fc-modification · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• A61K38/08

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• C12N2533/50

  Proteins · CPC title

• A61P31/22

  for herpes viruses · CPC title